Founded in March 2025, OTR Therapeutics operates a hybrid model that combines internal R&D with the strategic acquisition of promising external programs to accelerate drug development. Its R&D hub in Shanghai’s Zhangjiang Hi-Tech Park collaborates with partners across the U.S., Europe, and Asia to advance differentiated candidates addressing treatment gaps in immunology & inflammation, oncology, cardiometabolic, and neurological disorders. The company recently acquired a preclinical neurological program with best-in-class potential, underscoring its asset-curation strategy. Led by co-founders Zhui Chen, Ph.D., Shannon Chuai, Ph.D., and Yuan Shi, Ph.D., OTR emphasizes capital and development efficiency to push novel drug candidates into global clinical translation. Financially, the firm emerged from stealth with a $100 million Series A round in June 2025, providing significant runway for pipeline expansion and R&D hub growth. No revenue or clinical-stage metrics have been disclosed to date.

Total raised

$100M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025